CD274 and diffuse large B-cell lymphoma: With the development of the immune-oncology field and the advent of promising novel immunotherapy treatments, integration of these vulnerabilities into a framework may contribute to the rationale for PD-1/PD-L1-related combinational immunotherapy in DLBCL.